May Hill Capital’s Novartis NVS Stock Holding History

May Hill Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Buy	9,081 +62	+0.7%	+$9.29K	0.3%	62
2026 Q1	$1.38M	Buy	9,019 +1,404	+18%	+$215K	0.35%	55
2025 Q4	$1.05M	Buy	7,615 +110	+1%	+$14.4K	0.28%	65
2025 Q3	$962K	Buy	7,505 +1,231	+20%	+$150K	0.28%	60
2025 Q2	$759K	Buy	6,274 +2,084	+50%	+$235K	0.25%	68
2025 Q1	$467K	Buy	4,190 +1,466	+54%	+$156K	0.18%	86
2024 Q4	$265K	Buy	+2,724	New	+$290K	0.1%	130

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

May Hill Capital's NVS Position: Q2 2026 in Review

May Hill Capital increased its Novartis (NVS) stake by 0.69% in Q2 2026, buying an estimated $9.29K and bringing the position to 9,081 shares worth $1.42M. The position accounts for 0.3% of the portfolio, ranked #62.

May Hill Capital first reported a position in NVS in Q4 2024 and has held it in 7 quarters since. 1,623 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

May Hill Capital held 9,081 shares of Novartis worth $1.42M as of Q2 2026.
May Hill Capital bought 62 Novartis shares in Q2 2026, an estimated $9.29K.
Novartis made up 0.3% of May Hill Capital's portfolio in Q2 2026, its #62 holding.
May Hill Capital first reported a position in Novartis in Q4 2024 and has held it in 7 quarters since.
1,623 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on May Hill Capital's 13F filing for Q2 2026, filed 7 Aug 2026.